Sacubitril-valsartan, a common drug combination for heart failure, cuts the risk for cardiomyopathy after chemotherapy in patients who received anthracycline drugs by 77% in the first randomized ...
Hosted on MSN
Nanomedicine researchers restructure common chemo drug to boost its power by 20,000-fold
In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of a common chemotherapy drug, making it dramatically more soluble and ...
Most people who undergo chemotherapy do not develop heart failure. However, specific chemotherapy drugs may significantly increase your risk of heart failure and other cardiac problems. Chemotherapy ...
The team has already identified a short-list of dozens of high-priority targets. From this short-list, the team is now focused on one drug shows particular promise for proof of concept due to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results